A new treatment for advanced pancreatic cancer has been approved. This pill is intended for patients with metastatic pancreatic cancer who have already undergone chemotherapy. The medication will be marketed under a specific brand name and is manufactured by a particular company.

The cost of this treatment is approximately $39,800 for one month's supply. Further information about this development is available from various news sources, including The New York Times and The Associated Press.

Details about the treatment's effects and usage can be found through these sources, which have reported on the approval and its implications for patients with this type of cancer.